Abstract:Background Type 1 diabetes (T1D) is an autoimmune disease with a complex aetiology. B cells play an important role in the pathogenesis of T1D. Regulatory B cells (Bregs) are a subset of B cells that produce and secrete the inhibitory factor interleukin-10 (IL-10), thereby exerting an anti-inflammatory effect. It was recently discovered that T-cell immunoglobulin mucin domain 1 (Tim-1) is essential for maintaining Bregs function related to immune tolerance. However, the detailed understanding of Tim-1+ Bregs and IL-10+ Bregs in T1D patients is lacking. This study aimed to characterize the profile of B cell subsets in T1D patients compared with that in controls and determine whether Tim-1+ Bregs and IL-10+ Bregs play roles in T1D. Materials and Methods A total of 47 patients with T1D, 30 patients with type 2 diabetes (T2D) and 24 healthy controls were recruited in this study. Flow cytometry was used to measure the levels of different B cell subsets (including B cells, plasmablasts, and Bregs) in the peripheral blood. Radiobinding assays were performed to detect the antibody titres of T1D patients. In addition, the correlations between different B cell subsets and patient parameters were investigated. Results Compared with healthy controls, differences in frequency of Tim-1+ Bregs were significantly decreased in patients with T1D (36.53 ± 6.51 vs. 42.25 ± 6.83, P=0.02*), and frequency of IL-10+ Bregs were lower than healthy controls (17.64 ± 7.21vs. 24.52 ± 11.69, P=0.009**), the frequency of total Bregs in PBMC was also decreased in patients with T1D (1.42 ± 0.53vs. 1.99 ± 0.93, P=0.002.**). We analyzed whether these alterations in B cells subsets were associated with clinical features. The frequencies of Tim-1+ Bregs and IL-10+ Bregs were negatively related to fasting blood glucose (FBG) (r=-0.25 and -0.22; P=0.01* and 0.03*, respectively). The frequencies of Tim-1+ Bregs and IL-10+ Bregs are positively correlated with fast C-peptide (FCP) (r=0.23 and 0.37; P=0.02* and 0.0001***, respectively). In addition, the frequency of IL-10+ Breg was also negatively related to glycosylated haemoglobin (HbA1c) (r=-0.20, P=0.04*). The frequencies of Tim-1+ Bregs, IL-10+ Bregs and Bregs in T2D patients were reduced, but no statistically significant difference was found between other groups. Interestingly, there was positive correlation between the frequencies of Tim-1+ Bregs and IL-10+ Bregs in T1D (r=0.37, P=0.01*). Of note, it is worth noting that our study did not observe any correlations between B cell subsets and autoantibody titres. Conclusions Our study showed altered Tim-1 and IL-10 expression in regulatory B cell in T1D patients. Tim-1, as suggested by the present study, is associated with islet function and blood glucose levels. These findings indicate that Tim-1+ Bregs and IL-10+ Bregs were involved in the pathogenesis of T1D.

TLR9-deficiency in B Cells Promotes Immune Tolerance Via IL-10 in a Type 1 Diabetes Mouse Model

TLR9 Deficiency in B Cells Promotes Immune Tolerance via Interleukin-10 in a Type 1 Diabetes Mouse Model

Gut microbiota from B-cell-specific TLR9-deficient NOD mice promote IL-10+ Breg cells and protect against T1D

Toll-like Receptor 9 Negatively Regulates Pancreatic Islet Beta Cell Growth and Function in a Mouse Model of Type 1 Diabetes

TLR5-deficiency controls dendritic cell subset development in an autoimmune diabetes-susceptible model

IL-10 Deficiency Accelerates Type 1 Diabetes Development via Modulation of Innate and Adaptive Immune Cells and Gut Microbiota in BDC2.5 NOD Mice

Toll-like receptor 7 deficiency suppresses type 1 diabetes development by modulating B-cell differentiation and function.

Type-1 interferon induced cross-regulation of IL-10 function: a novel mechanism in type 1 diabetes development

Dynamic Number and Function of IL-10–Producing Regulatory B Cells in the Immune Microenvironment at Distinct Stages of Type 1 Diabetes

Beyond Knockout: A Novel Homodimerization-Targeting MyD88 Inhibitor Prevents and Cures Type 1 Diabetes in NOD Mice

Interleukin-10+ regulatory B cells arise within antigen-experienced CD40+ B cells to maintain tolerance to islet autoantigens

NLRP6 deficiency expands a novel CD103+ B cell population that confers immune tolerance in NOD mice

Essential Roles Of Tgf-Beta In Anti-Cd3 Antibody Therapy: Reversal Of Diabetes In Nonobese Diabetic Mice Independent Of Foxp3(+) Cd4(+) Regulatory T Cells

Foxp3-expressing CD4+T Cells under the Control of IFN-γ Promoter Prevent Diabetes in NOD Mice

Tolerogenic Vaccination Reduced Effector Memory Cd4 T Cells and Induced Effector Memory Treg Cells for Type I Diabetes Treatment

Involvement of Suppressive B-Lymphocytes in the Mechanism of Tolerogenic Dendritic Cell Reversal of Type 1 Diabetes in NOD Mice

Lipopolysaccharide-Activated B Cells Down-Regulate Th1 Immunity and Prevent Autoimmune Diabetes in Nonobese Diabetic Mice1

Prolonged exposure to type-I IFN inhibits IL-10 signaling in memory and regulatory T cells: a new mechanism contributing to the development of autoimmune diseases (BA13P.130)

Intestinal Type 1 Regulatory T Cells Migrate to Periphery to Suppress Diabetogenic T Cells and Prevent Diabetes Development

Elevated Glucose Metabolism Driving Pro-Inflammatory Response in B Cells Contributes to the Progression of Type 1 Diabetes.

Altered Tim-1 and IL-10 Expression in Regulatory B Cell Subsets in Type 1 Diabetes